{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barksdale BR"],"funding":["U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)","One Mind – Baszucki Brain Research Fund, SEAL Future Foundation","Texas Child Mental Health Consortium","NIMH NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)","U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism"],"pagination":["4497-4511"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12436151"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(10)"],"pubmed_abstract":["Mood, anxiety, and trauma-related disorders (MATRDs) are highly prevalent and comorbid. A sizable number of patients do not respond to first-line treatments. Non-invasive neuromodulation is a second-line treatment approach, but current methods rely on cortical targets to indirectly modulate subcortical structures, e.g., the amygdala, implicated in MATRDs. Low-intensity transcranial focused ultrasound (tFUS) is a non-invasive technique for direct subcortical neuromodulation, but its safety, feasibility, and promise as a potential treatment is largely unknown. In a target engagement study, magnetic resonance imaging (MRI)-guided tFUS to the left amygdala was administered during functional MRI (tFUS/fMRI) to test for acute modulation of blood oxygenation level dependent (BOLD) signal in a double-blind, within-subject, sham-controlled design in patients with MATRDs (N = 29) and healthy comparison subjects (N = 23). In an unblinded treatment trial, the same patients then underwent 3-week daily (15 sessions) MRI-guided repetitive tFUS (rtFUS) to the left amygdala to examine safety, feasibility, symptom change, and change in amygdala reactivity to emotional faces. Active vs. sham tFUS/fMRI reduced, on average, left amygdala BOLD signal and produced patient-related differences in hippocampal and insular responses. rtFUS was well-tolerated with no serious adverse events. There were significant reductions on the primary outcome (Mood and Anxiety Symptom Questionnaire General Distress subscale; p = 0.001, Cohen's d = 0.77), secondary outcomes (Cohen's d of 0.43-1.50), and amygdala activation to emotional stimuli. Findings provide initial evidence of tFUS capability to modulate amygdala function, rtFUS safety and feasibility in MATRDs, and motivate double-blind randomized controlled trials to examine efficacy.ClinicalTrials.gov registration: NCT05228964."],"journal":["Molecular psychiatry"],"pubmed_title":["Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial."],"pmcid":["PMC12436151"],"funding_grant_id":["R01MH125886","K23 MH114023","R01MH117292","R01 MH132784","R01AA021090","R01MH132784","R01MH129694","R01 MH117292","R01 MH129694","K23MH114023","R01 MH122387","R01 MH125886","R01MH122387"],"pubmed_authors":["Barksdale BR","Enten L","DeMarco A","Fonzo GA","Kline R","Doss MK","Nemeroff CB"],"additional_accession":[]},"is_claimable":false,"name":"Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial.","description":"Mood, anxiety, and trauma-related disorders (MATRDs) are highly prevalent and comorbid. A sizable number of patients do not respond to first-line treatments. Non-invasive neuromodulation is a second-line treatment approach, but current methods rely on cortical targets to indirectly modulate subcortical structures, e.g., the amygdala, implicated in MATRDs. Low-intensity transcranial focused ultrasound (tFUS) is a non-invasive technique for direct subcortical neuromodulation, but its safety, feasibility, and promise as a potential treatment is largely unknown. In a target engagement study, magnetic resonance imaging (MRI)-guided tFUS to the left amygdala was administered during functional MRI (tFUS/fMRI) to test for acute modulation of blood oxygenation level dependent (BOLD) signal in a double-blind, within-subject, sham-controlled design in patients with MATRDs (N = 29) and healthy comparison subjects (N = 23). In an unblinded treatment trial, the same patients then underwent 3-week daily (15 sessions) MRI-guided repetitive tFUS (rtFUS) to the left amygdala to examine safety, feasibility, symptom change, and change in amygdala reactivity to emotional faces. Active vs. sham tFUS/fMRI reduced, on average, left amygdala BOLD signal and produced patient-related differences in hippocampal and insular responses. rtFUS was well-tolerated with no serious adverse events. There were significant reductions on the primary outcome (Mood and Anxiety Symptom Questionnaire General Distress subscale; p = 0.001, Cohen's d = 0.77), secondary outcomes (Cohen's d of 0.43-1.50), and amygdala activation to emotional stimuli. Findings provide initial evidence of tFUS capability to modulate amygdala function, rtFUS safety and feasibility in MATRDs, and motivate double-blind randomized controlled trials to examine efficacy.ClinicalTrials.gov registration: NCT05228964.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-01T06:22:00.867Z","creation":"2026-04-08T09:46:36.14Z"},"accession":"S-EPMC12436151","cross_references":{"pubmed":["40275098"],"doi":["10.1038/s41380-025-03033-w"]}}